Purdue's Pain And No Gain: More Analysis Of OxyContin Postmarket Studies Needed

FDA cancels advisory committee once Purdue pulls sNDA, but firm plans to resubmit after 'building the most compelling body of epidemiological evidence' that reformulated product has meaningful impact on abuse.